Literature DB >> 12378629

Angiogenesis inhibitor TNP-470 suppresses growth of peritoneal disseminating foci of human colon cancer line Lovo.

Ying-Fang Fan1, Zong-Hai Huang.   

Abstract

AIM: To study the effect of angiogenesis inhibitor TNP-470 on peritoneal dissemination of colon cancer in nude mice.
METHODS: The MTT assay was used to evaluate the inhibitory effect of TNP-470 on human colon cancer cell line Lovo. Lovo cells were injected into the peritoneal cavity of BABL/C nu/nu mice and the models of peritoneal dissemination were developed. Thirty nude mice were randomly divided into control and TNP-470-treated group. In TNP-470-treated group, TNP-470 was injected subcutaneously every other day from day 1 until sacrifice or death (30 mg x kg(-1)). The control group received a sham injection of the same volume saline solution.
RESULTS: In vitro, TNP-470 inhibited the growth of Lovo cells, with its IC50 at 2.14 X 10(2) microg x L(-1). In vitro, TNP-470 demonstrated growth inhibition of tumors. Mice body weight and abdominal circumferences were significantly different between TNP-470-treated group (24.5+/-3.2 g, 7.0+/-1.1 cm) and control group (29.5+/-2.1 g, 10.3+/-1.5 cm), P=0.005 and P=0.001. The number of disseminated foci was significantly different between the control group (92.1+/-20.6) and the TNP-470-treated group (40.3+/-12.3), P<0.001. The maximal size of foci was significantly smaller in TNP-470-treated group (3.3+/-0.7 mm) than that of control (7.3+/-2.3 mm), P=0.004. Mean survival time was significantly longer in TNP-470-treated group(98.00+/-12.06 d) than that in control group (41.86+/-9.51 d), P<0.001.
CONCLUSION: Angiogenesis inhibitor TNP-470 might be effective in treating peritoneal dissemination of colon cancer and improve the survival rate of nude mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378629      PMCID: PMC4656574          DOI: 10.3748/wjg.v8.i5.853

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  48 in total

Review 1.  Tumor interactions with the vasculature: angiogenesis and tumor metastasis.

Authors:  C H Blood; B R Zetter
Journal:  Biochim Biophys Acta       Date:  1990-06-01

2.  Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2.

Authors:  E C Griffith; Z Su; S Niwayama; C A Ramsay; Y H Chang; J O Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle.

Authors:  N Antoine; R Greimers; C De Roanne; M Kusaka; E Heinen; L J Simar; V Castronovo
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

4.  The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.

Authors:  N Sin; L Meng; M Q Wang; J J Wen; W G Bornmann; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  Proceedings: Tumor angiogenesis factor.

Authors:  J Folkman
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

6.  Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.

Authors:  S Wojtowicz-Praga; J Low; J Marshall; E Ness; R Dickson; J Barter; M Sale; P McCann; J Moore; A Cole; M J Hawkins
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

7.  Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases.

Authors:  J Wang; P Lou; J Henkin
Journal:  J Cell Biochem       Date:  2000-04       Impact factor: 4.429

8.  Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470).

Authors:  M Yamaoka; T Yamamoto; T Masaki; S Ikeyama; K Sudo; T Fujita
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

9.  A dominant negative mutation in Saccharomyces cerevisiae methionine aminopeptidase-1 affects catalysis and interferes with the function of methionine aminopeptidase-2.

Authors:  M Klinkenberg; C Ling; Y H Chang
Journal:  Arch Biochem Biophys       Date:  1997-11-15       Impact factor: 4.013

10.  Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470).

Authors:  C N Qian; H Q Min; H L Lin; M H Hong; Y L Ye
Journal:  J Laryngol Otol       Date:  1998-09       Impact factor: 1.469

View more
  5 in total

Review 1.  Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers.

Authors:  E M V de Cuba; R Kwakman; M van Egmond; L J W Bosch; H J Bonjer; G A Meijer; E A te Velde
Journal:  Virchows Arch       Date:  2012-07-24       Impact factor: 4.064

2.  The study of chemiluminescence in gastric and colonic carcinoma cell lines treated by anti-tumor drugs.

Authors:  Che Chen; Fu-Kun Liu; Xiao-Ping Qi; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

3.  Effects of TNP-470 on proliferation and apoptosis in human colon cancer xenografts in nude mice.

Authors:  Zong-Hai Huang; Ying-Fang Fan; Hu Xia; Hao-Miao Feng; Fu-Xiang Tang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

4.  Role of inducible nitric oxide synthase expression in aberrant crypt foci-adenoma-carcinoma sequence.

Authors:  Mei-Hua Xu; Chang-Sheng Deng; You-Qing Zhu; Jun Lin
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

5.  Aging erythrocyte membranes as biomimetic nanometer carriers of liver-targeting chromium poisoning treatment.

Authors:  Qing Yao; Guobao Yang; Hao Wang; Jingzhou Liu; Jinpeng Zheng; Bai Lv; Meiyan Yang; Yang Yang; Chunsheng Gao; Yongxue Guo
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.